ストックスクリーナーアプリを入手
108.62
1.06%
1.14
アフターアワーズ：
104.04
-4.58
-4.22%
Mirum Pharmaceuticals Inc (MIRM) 最新ニュース
Mirum Pharmaceuticals Reports Strong Q4 2025 Earnings and 2026 Guidance - Intellectia AI
Mirum Pharmaceuticals (MIRM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Mirum Pharmaceuticals Files For Offering Of Up To 8.96 Million Shares Of Common Stock By The Selling Stockholders - TradingView
Mirum (MIRM) Q4 2025 Earnings Call Transcript - AOL.com
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), Mirum Pharmaceuticals, Inc. has officially registered a public offering plan of common stock initiated by selling shareholders. - Bitget
Earnings call transcript: Mirum Pharmaceuticals’ Q4 2025 revenue exceeds expectations - Investing.com
Mirum Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update - Business Wire
Mirum Pharmaceuticals earnings up next as pipeline readouts loom - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Biotech Powerhouse with 9.63% Potential Upside - DirectorsTalk Interviews
Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its 115% One-Year Surge? - Yahoo Finance
Insights Ahead: Mirum Pharmaceuticals's Quarterly Earnings - Benzinga
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - bdtonline.com
Will Mirum Pharmaceuticals Inc. stock hit new highs in YEARJuly 2025 Snapshot & Weekly High Return Stock Forecasts - mfd.ru
Mirum Pharmaceuticals (NASDAQ:MIRM) Research Coverage Started at Royal Bank Of Canada - Defense World
Portfolio Recap: Will Mirum Pharmaceuticals Inc stock hit new highs in YEARJuly 2025 Review & Risk Controlled Daily Plans - baoquankhu1.vn
Mirum Pharmaceuticals (NASDAQ:MIRM) Raised to "Moderate Buy" at Royal Bank Of Canada - MarketBeat
Mirum Pharmaceuticals stock reaches all-time high at 106.27 USD By Investing.com - Investing.com Canada
Earnings Recap: Can Mirum Pharmaceuticals Inc benefit from deglobalizationJuly 2025 Trends & Free Community Consensus Stock Picks - baoquankhu1.vn
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 - Bluefield Daily Telegraph
Drugmaker Mirum sets Feb. 25 call on 2025 results - Stock Titan
User - The Chronicle-Journal
RBC Capital Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Outperform Recommendation - Nasdaq
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week HighTime to Buy? - MarketBeat
Mirum Can Sustain Revenue Growth with Multiple Catalysts, RBC Says - marketscreener.com
Mirum Pharmaceuticals stock reaches all-time high at 106.27 USD - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Yahoo Finance
Mirum Pharmaceuticals (MIRM) Expected to Announce Earnings on Wednesday - MarketBeat
Saira Ramasastry, Mirum director, sells $204k in shares By Investing.com - Investing.com Canada
Saira Ramasastry, Mirum director, sells $204k in shares - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Biotech Gem with 11.25% Upside Potential - DirectorsTalk Interviews
TimesSquare Capital Management LLC Makes New $22.04 Million Investment in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Is Mirum Pharmaceuticals Inc. a turnaround storyDollar Strength & Real-Time Stock Price Movement Reports - mfd.ru
Why Mirum Pharmaceuticals Inc. stock is trending among retail traders - mfd.ru
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy - ChartMill
What are analysts’ price targets for Mirum Pharmaceuticals Inc.Earnings Summary Report & Weekly Sector Rotation Insights - mfd.ru
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will Mirum Pharmaceuticals Inc. benefit from AI trendsShare Buyback & Expert Verified Stock Movement Alerts - mfd.ru
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MEXC
Mirum Pharmaceuticals Grants Stock Awards to New Employees - Intellectia AI
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup - ChartMill
Candriam S.C.A. Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals expands portfolio in rare disease drug focus - Traders Union
Gap Down: Can Mirum Pharmaceuticals Inc benefit from deglobalizationJuly 2025 PreEarnings & Fast Entry Momentum Alerts - baoquankhu1.vn
Health Canada approves Livmarli for PFIC and ALGS - The Pharma Letter
Mirum Pharmaceuticals, Inc. $MIRM Shares Purchased by Penserra Capital Management LLC - MarketBeat
Sentiment Review: Is Mirum Pharmaceuticals Inc a turnaround storyFed Meeting & Safe Entry Trade Signal Reports - baoquankhu1.vn
Health Canada LIVMARLI Decision And Bluejay Deal Shape Mirum Outlook - Yahoo Finance
Mirum Pharmaceuticals says Health Canada authorizes Livmarli for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC) patients - marketscreener.com
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome - BioSpace
Mirum Pharmaceuticals Stumbles on Health Canada Approval - Baystreet.ca
Mirum Pharmaceuticals' Tablet Formulation of its Cholestasic Pruritus Treatment Livmarli Approved in Canada - marketscreener.com
for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) - Business Wire
Is Mirum Pharmaceuticals on a Strong Path to Profitability? - AOL.com
Hot Picks: Small-cap pharma stocks in focus as key drug approvals near - BNN Bloomberg
1.52%
1.68%
大文字化:
|
ボリューム (24 時間):